Concern has been raised about the number of juvenile animal studies (JAS) being conducted in the European
Union (EU) and the number of species required. The question of whether there has been an increase
in the number of JAS requested by European Medicines Agency (EMA) and the question of single or multiple
species studies are the focus of this manuscript. All source data on Pediatric Investigation Plans (PIP)
were obtained from EMA pediatrics website and evaluated by year as obtained and adjusted to the date
of the original PIP agreement rather than the newly assigned date of the PIP modification. The analysis
of the data originally suggested an increase in the number of juvenile animal studies per year post 2010.
However, a thorough examination of the adjusted PIP data from the EMA from December 2007 through
2013 support that the number of JAS being included in PIPs per year is not increasing but is in fact fairly
stable at 15–30% per year. The data also, as expected, support that the JAS are mostly proposed with a
single species and that species is predominately the rat and that multi-species JAS for an agreed PIP are
infrequent.